Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.640
+0.210 (14.69%)
At close: Oct 9, 2025, 4:00 PM EDT
1.640
0.00 (0.00%)
Pre-market: Oct 10, 2025, 7:00 AM EDT
Lexicon Pharmaceuticals Employees
Lexicon Pharmaceuticals had 103 employees as of December 31, 2024. The number of employees decreased by 182 or -63.86% compared to the previous year.
Employees
103
Change (1Y)
-182
Growth (1Y)
-63.86%
Revenue / Employee
$567,301
Profits / Employee
-$1,171,068
Market Cap
595.97M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 103 | -182 | -63.86% |
Dec 31, 2023 | 285 | 150 | 111.11% |
Dec 31, 2022 | 135 | 48 | 55.17% |
Dec 31, 2021 | 87 | 9 | 11.54% |
Dec 31, 2020 | 78 | -106 | -57.61% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
LXRX News
- 1 day ago - Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain - GlobeNewsWire
- 17 days ago - Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 23 days ago - Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - GlobeNewsWire